We conclude that therapy with certolizumab pegol for 12 weeks significantly decreased clinical (tender and inflammatory joint counts) and biological (RF, anti-CCP, ESR and CRP) activity in our patients with RA, particularly in the subpopulation with higher inflammatory burden at baseline. This evidence concerns the gene CRP and rheumatoid arthritis.